Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Webinars
and Events

Expert Perspectives in Colorectal Cancer Care

- video series 2 (ESMO-GI)

Join our Expert Faculty to learn about clinical areas of interest in the management of colorectal cancer, to hear their practical experience-based insights on a range of topics.

 

These include discussing the current main challenges in the management of mCRC, the importance of anti-angiogenic activity in the management of this disease and the changing ages of patients presenting with advanced colorectal cancer and discussing optimal treatment sequenciing options, as well as reviewing a typical patient profile for regorafenib treatment.

 

Expert faculty includes Dr Sheela Rao, London, Dr Harpreet Wasan, London and Dr Elena Elez, Barcelona.

 

This video series is organised and funded by Bayer plc.

Video 1
Video 1

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Video 2
Video 2

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Video 3
Video 3

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Speakers

Dr Sheela Rao

Dr Sheela Rao

Dr Rao is a Consultant Medical Oncologist specialising in gastrointestinal cancers and cancers of unknown primary within the Gastrointestinal Unit at the Royal Marsden Hospital. Dr Rao completed medical training at Charing Cross and Westminster Medical School and specialist oncology training at The Royal Marsden. She undertook laboratory-based research at The Institute of Cancer Research, supported by an academic grant, examining the prognostic and predictive value of genomic profiling of tumour biopsies in oesophago-gastric cancer. She is The Royal Marsden's lead for cancers of unknown primary. Her research interests include clinical trials with novel therapies in GI cancers and she is the Principal investigator on a number of national and international trials with novel agents and immunotherapy. She serves on the committees for the UK National Cancer Research Institute (NCRI) Colorectal Cancer and Anal-Rectal Clinical Study Groups and is an active member of the International Rare Cancers Initiative (IRCI). She serves on the European Society of Medical Oncology (ESMO) educational faculty for GI Tumours. She sits on a number of national and international trial management groups and data monitoring committees.

Dr Harpreet Wasan

Dr Harpreet Wasan

Harpreet Wasan is a Professor in Medical Oncology and leads the gastrointestinal clinical research program at Hammersmith Hospital, Imperial College London and is current Lead for Cancer for The N.W. London NIHR Research network. His research interests cover CRC, Biliary, Pancreatic Cancer & CUP and has led and participated in trials that have led to global new standards of care with interests in designing and implementing novel paradigm & interventional trials (including non-drug interventions) in GI cancer.

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.

OPT-IN TO BAYER COMMUNICATIONS OPT-IN TO BAYER COMMUNICATIONS

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.

 

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.